Oppenheimer analyst Colin Rusch maintains Albemarle (NYSE:ALB) with a Outperform and raises the price target from $497 to $498.
Ironwood Pharmaceuticals Q4 Adj. EPS $0.27 Misses $0.35 Estimate, Sales $117.13M Beat $109.87M Estimate
Ironwood Pharmaceuticals (NASDAQ:IRWD) reported quarterly earnings of $0.27 per share which missed the analyst consensus estimate of $0.35 by 22.86 percent. This is a 25 percent decrease over earnings of $0.36 per share
